# Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

> **NCT02930018** · PHASE3 · COMPLETED · sponsor: **NoNO Inc.** · enrollment: 1105 (actual)

## Conditions studied

- Stroke, Acute

## Interventions

- **DRUG:** Nerinetide (NA-1), 2.6 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02930018
- **Lead sponsor:** NoNO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2019-11-20
- **Final completion:** 2019-11-20
- **Target enrollment:** 1105 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930018, "Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02930018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*